Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person *- Benaim Ely				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 01/26/2018						X	X Officer (give title below) Other (specify below) Chief Medical Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
ROCKVI	LLE, MD	20850 (State)	(Zip)												
									ative Securitie		•				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				2A. Deemed Execution Da any (Month/Day/		ate, if Co		8) (A. Securities Acq A) or Disposed Instr. 3, 4 and 5	of (D) Ow Tra	Transaction(s) (Instr. 3 and 4)		ed (Ownership of B	eneficial wnership
Reminder:	Report on a	separate line for eac	Table II - I	Derivativo	e Se	curities .	Acqı	Persor contai form d	ns who responed in this for isplays a currosed of, or Ben	rm are no rently vali eficially O	t require d OMB c	d to respo	nd unless th		174 (9-02)
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number		options, convertible secure 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab	Expiration le Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 2.29	01/26/2018		A		45,443		<u>(1)</u>	01/26/2028	Commo	n 45,443	\$ 0	45,443	D	
Repor	ting O	wners													

Reporting Owner Name / Address	Relationships						
reporting 6 wher Funde / Funde ess	Director	ector 10% Owner Officer		Other			
Benaim Ely C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850			Chief Medical Officer				

Signatures

/s/ Douglas J. Swirsky, as attorney-in-fact for Ely Benaim	01/30/2018	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One quarter of the option vests and becomes exercisable on January 26, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.